Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
According to the company, GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available. The product is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This regenerative approach could offer a significant advantage over existing treatments, which often involve multiple steps or cell-based therapies.
The training program at Humanitas Research Hospital, a leading orthopedic center, will serve as a model for future sessions across Europe. By establishing Centers of Excellence, Regentis aims to build a network of skilled surgeons who can effectively use GelrinC and share best practices. This strategy is crucial for gaining traction in the European market, where regulatory approval has already been secured.
The announcement comes as Regentis advances its commercial plans following CE Mark approval. The company’s focus on surgeon education reflects a common challenge in medical device commercialization: ensuring that clinicians are comfortable and proficient with new technologies. With GelrinC’s potential to address a large unmet need in knee cartilage repair, successful training could drive adoption and improve patient outcomes.
For more details, the full press release is available at https://ibn.fm/QOWWK. Forward-looking statements in this article involve risks and uncertainties, as detailed in Regentis’ filings with the SEC. Readers are cautioned not to place undue reliance on these statements, which reflect management’s views as of the date hereof.
